China Regulatory Affairs Outsourcing Market Size & Outlook
The regulatory affairs outsourcing market in China is expected to reach a projected revenue of US$ 1,392.2 million by 2030. A compound annual growth rate of 10% is expected of China regulatory affairs outsourcing market from 2024 to 2030.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
In Asia Pacific, Japan regulatory affairs outsourcing market is projected to lead the regional market in terms of revenue in 2030.
India is the fastest growing regional market in Asia Pacific and is projected to reach USD 1,056.9 million by 2030.
China is one of the most attractive markets for the biopharmaceutical industry. The growing geriatric population and the presence of a large pool of population belonging to the middle-income group are further increasing the demand for innovative and cost-effective medicines, which is expected to attract major biopharmaceutical and medical device companies in this region.
Seeking approval for new drugs is a primary challenge faced by biopharmaceutical companies as a clinical trial application process requires 12 to 24 months while the approval process may require more than six years.
Along with national approvals, the new drug requires approval at both the provincial or city levels, which may require an additional four to five years. Reforms in the healthcare sector in recent times are expected to streamline the approval process.
China Regulatory Affairs Outsourcing Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Regulatory Affairs Outsourcing Market Outlook will help companies and investors design strategic landscapes.
Product Registration & Clinical Trial Applications was the largest segment with a revenue share of 25.99% in 2023.
Horizon Databook has segmented the China regulatory affairs outsourcing market based on regulatory consulting, legal representation, regulatory writing & publishing, product registration & clinical trial applications, regulatory submissions, regulatory operations, other services covering the revenue growth of each sub-segment from 2018 to 2030.
China is one of the most attractive markets for the biopharmaceutical industry. The growing geriatric population and the presence of a large pool of population belonging to the middle-income group are further increasing the demand for innovative and cost-effective medicines, which is expected to attract major biopharmaceutical and medical device companies in this region.
Seeking approval for new drugs is a primary challenge faced by biopharmaceutical companies as a clinical trial application process requires 12 to 24 months while the approval process may require more than six years.
Along with national approvals, the new drug requires approval at both the provincial or city levels, which may require an additional four to five years. Reforms in the healthcare sector in recent times are expected to streamline the approval process.
China Regulatory Affairs Outsourcing Market Service Outlook (Revenue, USD Million , 2018-2030)
China Regulatory Affairs Outsourcing Market Category Outlook (Revenue, USD Million , 2018-2030)
Drugs
Biologics
Medical Devices
China Regulatory Affairs Outsourcing Market End-User Outlook (Revenue, USD Million , 2018-2030)
Biotechnology Companies
Pharmaceutical Companies
Medical Device Companies
China Regulatory Affairs Outsourcing Market Company Size Outlook (Revenue, USD Million , 2018-2030)
Small
Medium
Large
China Regulatory Affairs Outsourcing Market Indication Outlook (Revenue, USD Million , 2018-2030)
Oncology
Neurology
Cardiology
Immunology
Others
China Regulatory Affairs Outsourcing Market Stage Outlook (Revenue, USD Million , 2018-2030)
Preclinical
Clinical studies
PMA
Reasons to subscribe to Regulatory Affairs Outsourcing Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Regulatory Affairs Outsourcing Market Outlook databook
Our clientele includes a mix of Regulatory Affairs Outsourcing Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the China Regulatory Affairs Outsourcing Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into China Regulatory Affairs Outsourcing Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.
China Regulatory Affairs Outsourcing Market, 2018-2030 (US$M)